Targeting the Resistance in Multiple Myeloma
Multiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-04-01
|
| Series: | Proceedings |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2504-3900/11/1/3 |
| _version_ | 1811280959060836352 |
|---|---|
| author | Micaela Freitas Mark E. Issa Muriel Cuendet |
| author_facet | Micaela Freitas Mark E. Issa Muriel Cuendet |
| author_sort | Micaela Freitas |
| collection | DOAJ |
| description | Multiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic strategies to overcome this resistance, which is partly attributed to a subpopulation of cells known as cancer stem cells. Withanolides and HDAC6 selective inhibitors were identified as promising compounds in various resistant multiple myeloma models. |
| first_indexed | 2024-04-13T01:25:13Z |
| format | Article |
| id | doaj.art-368d1684736041999f5710d616a90adb |
| institution | Directory Open Access Journal |
| issn | 2504-3900 |
| language | English |
| last_indexed | 2024-04-13T01:25:13Z |
| publishDate | 2019-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Proceedings |
| spelling | doaj.art-368d1684736041999f5710d616a90adb2022-12-22T03:08:39ZengMDPI AGProceedings2504-39002019-04-01111310.3390/proceedings2019011003proceedings2019011003Targeting the Resistance in Multiple MyelomaMicaela Freitas0Mark E. IssaMuriel CuendetSchool of pharmaceutical sciences, University of Geneva, University of Lausanne, Rue Michel-Servet 1, 1211 Geneva, SwitzerlandMultiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic strategies to overcome this resistance, which is partly attributed to a subpopulation of cells known as cancer stem cells. Withanolides and HDAC6 selective inhibitors were identified as promising compounds in various resistant multiple myeloma models.https://www.mdpi.com/2504-3900/11/1/3multiple myeloma3D co-culture modelcancer resistance |
| spellingShingle | Micaela Freitas Mark E. Issa Muriel Cuendet Targeting the Resistance in Multiple Myeloma Proceedings multiple myeloma 3D co-culture model cancer resistance |
| title | Targeting the Resistance in Multiple Myeloma |
| title_full | Targeting the Resistance in Multiple Myeloma |
| title_fullStr | Targeting the Resistance in Multiple Myeloma |
| title_full_unstemmed | Targeting the Resistance in Multiple Myeloma |
| title_short | Targeting the Resistance in Multiple Myeloma |
| title_sort | targeting the resistance in multiple myeloma |
| topic | multiple myeloma 3D co-culture model cancer resistance |
| url | https://www.mdpi.com/2504-3900/11/1/3 |
| work_keys_str_mv | AT micaelafreitas targetingtheresistanceinmultiplemyeloma AT markeissa targetingtheresistanceinmultiplemyeloma AT murielcuendet targetingtheresistanceinmultiplemyeloma |